The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and ...

Together, Mounjaro and Zepbound brought in $11.98 billion in the third quarter even with price decreases for the medicines.

Worth noting, CVS Caremark—the biggest PBM in the U.S.— announced in May that it would make Novo Nordisk’s rival drug Wegovy ...

Eli Lilly and Company LLY reported third-quarter 2025 adjusted earnings per share (“EPS”) of $7.02, which beat the Zacks ...

U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...

While the pharma giant Eli Lilly has lagged behind the broader market over the past year, it has outpaced the health care space, and analysts remain strongly bullish on the stock’s prospects.

Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...

Eli Lilly said on Thursday its experimental weight-loss pill met most criteria for the U.S. Food and Drug Administration's ...

A rendering of Eli Lilly's planned plant expansion in Pleasant Prairie. The company is preparing for a next phase on a site ...

With quarterly revenue up 54% from a year ago, Eli Lilly raised it guidance for the year, with the company now expecting revenue in the range of $63 billion to $63.5 billion ...

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, ...

In the third quarter, Lilly earned $7.02 per share on an adjusted basis, far above the $5.69 analysts were expecting, ...